Instructions for Use
FDA Benefit-Risk Paradigm AGA-FDA Regulatory/Reimbursement Workshop
FDA approves implant designed to treat obesity by zapping nerves | CTV News
Summary of Safety and Effectiveness Data (SSED)
EnteroMedics Announces FDA Approval of VBLOC® Vagal Blocking Therapy for the Treatment of Obesity
EnteroMedics, Inc., St. Paul | Twin Cities Business
Amendment No. 7 to Form S-1
New ENTEROMEDICS Neuroregulator Rechargeable Neuroregulator Neurology General For Sale - DOTmed Listing #3394210:
EnteroMedics says study bolsters case for its obesity device
Pacemaker for the Stomach' Wins FDA Nod | mddionline.com
The Maestro Rechargeable System - New Weight-Loss Surgical Product Approved By FDA - Clinique Michel Gagner
FDA Executive Summary
Maestro Rechargeable System | The Implantable Appetite "Pacemaker"
Regulatory Submission Template
Newly Approved Weight Loss Device Blocks the Vagus Nerve
Unique ways to lose weight get FDA nods
Medical devices for the treatment of obesity | Nature Reviews Gastroenterology & Hepatology
The Maestro Rechargeable System- EnteroMedics
g50921mo01i001.jpg
Implantable neurostimulator - vBloc® Maestro® - EnteroMedics - for vagus nerve stimulation
EnteroMedics says study bolsters case for its obesity device
Latest weight loss surgery finds slim support from insurers
Hunger game: FDA approves new obesity fighter
FDA approves EnteroMedics' medical device to treat obesity | Business Insurance
Expansion of Maestro Rechargeable system's use - Today's Medical Developments
MC2402 Maestro Rechargeable System Mobile Charger Label Diagram P01429-001 Label Enteromedics, .
